Literature DB >> 29096386

Cannabis induced psychosis and subsequent psychiatric disorders.

Dharav Shah1, Prabhat Chand2, Mrunal Bandawar3, Vivek Benegal4, Pratima Murthy5.   

Abstract

INTRODUCTION: Long term change in diagnosis of patients having Cannabis induced psychosis (CIP) at the index evaluation is well recognised. Some patients are known to achieve complete remission while others go on to develop independent schizophrenia or mood disorders. AIMS: To study the long-term course of CIP and factors influencing it.
METHOD: Patients diagnosed as CIP (ICD 10: F12.5), admitted at NIMHANS, a tertiary neuropsychiatry centre at Bangalore, over the past 10 years were identified from medical records. 200 case records were identified and screened in detail. 57 met inclusion criteria and 35 patients could be followed up. Mean follow up duration was 5.75 years.
RESULTS: Patients who completely abstained from cannabis after the 1st episode had no relapse of psychiatric illness. They showed marked improvement in socio-occupational functioning as well. All those who relapsed to cannabis use had a recurrence of illness. Half the patients with predominantly non-affective psychosis progressed to an independent psychiatric disorder; while only 7.7% patients with predominantly affective psychosis developed an independent disorder (p=0.01). Besides this, early onset of cannabis use (≤18years), younger age at onset of 1st episode, positive family history of psychiatric illness, being unmarried and lower socio-economic status were associated with poor prognosis. Abstinence later in the course of illness did not improve outcome significantly.
CONCLUSION: Abstaining from cannabis early in the course of illness is critical for good recovery. The course of CIP is variable and categorising CIP into affective vs. non-affective psychosis can be useful in clinical practice.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cannabis; Cannabis induced psychosis; Follow up; Long term course; Substance induced psychosis

Mesh:

Year:  2017        PMID: 29096386     DOI: 10.1016/j.ajp.2017.10.003

Source DB:  PubMed          Journal:  Asian J Psychiatr        ISSN: 1876-2018


  7 in total

Review 1.  Cannabis Legalization and College Mental Health.

Authors:  Ludmila De Faria; Lillian Mezey; Aaron Winkler
Journal:  Curr Psychiatry Rep       Date:  2021-03-03       Impact factor: 5.285

Review 2.  Combinatorial approaches for treating neuropsychiatric social impairment.

Authors:  Don Wei; Sherab Tsheringla; James C McPartland; A Z A Stephen Azariah Allsop
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2022-07-11       Impact factor: 6.671

Review 3.  Cannabis Use and its Association with Psychological Disorders.

Authors:  Ivan Urits; Kyle Gress; Karina Charipova; Nathan Li; Amnon A Berger; Elyse M Cornett; Jamal Hasoon; Hisham Kassem; Alan D Kaye; Omar Viswanath
Journal:  Psychopharmacol Bull       Date:  2020-05-19

4.  Transition of Substance-Induced, Brief, and Atypical Psychoses to Schizophrenia: A Systematic Review and Meta-analysis.

Authors:  Benjamin Murrie; Julia Lappin; Matthew Large; Grant Sara
Journal:  Schizophr Bull       Date:  2020-04-10       Impact factor: 9.306

Review 5.  Substance-Induced Psychoses: An Updated Literature Review.

Authors:  Alessio Fiorentini; Filippo Cantù; Camilla Crisanti; Guido Cereda; Lucio Oldani; Paolo Brambilla
Journal:  Front Psychiatry       Date:  2021-12-23       Impact factor: 4.157

6.  Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis.

Authors:  Tabea Schoeler; Jason Ferris; Adam R Winstock
Journal:  Transl Psychiatry       Date:  2022-09-06       Impact factor: 7.989

7.  Oral Cannabidiol Use in Children With Autism Spectrum Disorder to Treat Related Symptoms and Co-morbidities.

Authors:  Dana Barchel; Orit Stolar; Tal De-Haan; Tomer Ziv-Baran; Naama Saban; Danny Or Fuchs; Gideon Koren; Matitiahu Berkovitch
Journal:  Front Pharmacol       Date:  2019-01-09       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.